Letters
Volume 32—2026
Volume 31—2025
Volume 30—2024
Volume 29—2023
Volume 28—2022
Volume 27—2021
Volume 26—2020
Volume 25—2019
Volume 24—2018
Volume 23—2017
Volume 22—2016
Volume 31—2025
Volume 30—2024
Volume 29—2023
Volume 28—2022
Volume 27—2021
Volume 26—2020
Volume 25—2019
Volume 24—2018
Volume 23—2017
Volume 22—2016
Volume 32—2026
Volume 32, Number 8—August 2026
Tuberculosis after Preventive Therapy in Persons Living with HIV Initiating Antiretroviral Therapy [PDF - 238 KB - 2 pages]
| EID | Chen Q. Tuberculosis after Preventive Therapy in Persons Living with HIV Initiating Antiretroviral Therapy. Emerg Infect Dis. 2026;32(8):1382-1383. https://doi.org/10.3201/eid3208.260493 |
|---|---|
| AMA | Chen Q. Tuberculosis after Preventive Therapy in Persons Living with HIV Initiating Antiretroviral Therapy. Emerging Infectious Diseases. 2026;32(8):1382-1383. doi:10.3201/eid3208.260493. |
| APA | Chen, Q. (2026). Tuberculosis after Preventive Therapy in Persons Living with HIV Initiating Antiretroviral Therapy. Emerging Infectious Diseases, 32(8), 1382-1383. https://doi.org/10.3201/eid3208.260493. |
Tuberculosis after Preventive Therapy in Persons Living with HIV Initiating Antiretroviral Therapy (Response) [PDF - 211 KB - 1 page]
| EID | Templin L, Varajidas Y, Respeito D, Zindoga P, Weiss D, Nguimfack A, et al. Tuberculosis after Preventive Therapy in Persons Living with HIV Initiating Antiretroviral Therapy (Response). Emerg Infect Dis. 2026;32(8):1383. https://doi.org/10.3201/eid3208.260828 |
|---|---|
| AMA | Templin L, Varajidas Y, Respeito D, et al. Tuberculosis after Preventive Therapy in Persons Living with HIV Initiating Antiretroviral Therapy (Response). Emerging Infectious Diseases. 2026;32(8):1383. doi:10.3201/eid3208.260828. |
| APA | Templin, L., Varajidas, Y., Respeito, D., Zindoga, P., Weiss, D., Nguimfack, A....José, B. (2026). Tuberculosis after Preventive Therapy in Persons Living with HIV Initiating Antiretroviral Therapy (Response). Emerging Infectious Diseases, 32(8), 1383. https://doi.org/10.3201/eid3208.260828. |
Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum [PDF - 475 KB - 2 pages]
| EID | Beale MA, Marks M, Luetkemeyer A, Celum C, Golden MR, Giacani L, et al. Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum. Emerg Infect Dis. 2026;32(8):1384-1385. https://doi.org/10.3201/eid3208.260433 |
|---|---|
| AMA | Beale MA, Marks M, Luetkemeyer A, et al. Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum. Emerging Infectious Diseases. 2026;32(8):1384-1385. doi:10.3201/eid3208.260433. |
| APA | Beale, M. A., Marks, M., Luetkemeyer, A., Celum, C., Golden, M. R., Giacani, L....Lieberman, N. (2026). Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum. Emerging Infectious Diseases, 32(8), 1384-1385. https://doi.org/10.3201/eid3208.260433. |
Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum (Response) [PDF - 212 KB - 1 page]
| EID | Long GS, Duvvuri VR. Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum (Response). Emerg Infect Dis. 2026;32(8):1385. https://doi.org/10.3201/eid3208.260943 |
|---|---|
| AMA | Long GS, Duvvuri VR. Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum (Response). Emerging Infectious Diseases. 2026;32(8):1385. doi:10.3201/eid3208.260943. |
| APA | Long, G. S., & Duvvuri, V. R. (2026). Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum (Response). Emerging Infectious Diseases, 32(8), 1385. https://doi.org/10.3201/eid3208.260943. |
Volume 32, Number 5—May 2026
Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina [PDF - 235 KB - 1 page]
| EID | Abravanel F, Castille C, Marter N, Guerin J, Lhomme S, Izopet J. Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina. Emerg Infect Dis. 2026;32(5):830. https://doi.org/10.3201/eid3205.260304 |
|---|---|
| AMA | Abravanel F, Castille C, Marter N, et al. Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina. Emerging Infectious Diseases. 2026;32(5):830. doi:10.3201/eid3205.260304. |
| APA | Abravanel, F., Castille, C., Marter, N., Guerin, J., Lhomme, S., & Izopet, J. (2026). Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina. Emerging Infectious Diseases, 32(5), 830. https://doi.org/10.3201/eid3205.260304. |
Evidence Lacking for Endemic Chagas Disease in the United States [PDF - 245 KB - 2 pages]
| EID | Cantey PT, Hast M, Chancey RJ, Mongomery SP. Evidence Lacking for Endemic Chagas Disease in the United States. Emerg Infect Dis. 2026;32(5):830-831. https://doi.org/10.3201/eid3205.251840 |
|---|---|
| AMA | Cantey PT, Hast M, Chancey RJ, et al. Evidence Lacking for Endemic Chagas Disease in the United States. Emerging Infectious Diseases. 2026;32(5):830-831. doi:10.3201/eid3205.251840. |
| APA | Cantey, P. T., Hast, M., Chancey, R. J., & Mongomery, S. P. (2026). Evidence Lacking for Endemic Chagas Disease in the United States. Emerging Infectious Diseases, 32(5), 830-831. https://doi.org/10.3201/eid3205.251840. |
Evidence Lacking for Endemic Chagas Disease in the United States (Response) [PDF - 205 KB - 1 page]
| EID | Beatty NL, Hamer GL, Moreno-Peniche B, Mayes B, Hamer SA. Evidence Lacking for Endemic Chagas Disease in the United States (Response). Emerg Infect Dis. 2026;32(5):831. https://doi.org/10.3201/eid3205.260617 |
|---|---|
| AMA | Beatty NL, Hamer GL, Moreno-Peniche B, et al. Evidence Lacking for Endemic Chagas Disease in the United States (Response). Emerging Infectious Diseases. 2026;32(5):831. doi:10.3201/eid3205.260617. |
| APA | Beatty, N. L., Hamer, G. L., Moreno-Peniche, B., Mayes, B., & Hamer, S. A. (2026). Evidence Lacking for Endemic Chagas Disease in the United States (Response). Emerging Infectious Diseases, 32(5), 831. https://doi.org/10.3201/eid3205.260617. |
Page created: March 23, 2026
Page updated: July 27, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
